BTG makes progress

Specialist pharmaceutical group BTG (BTG) saw its shares rise 9 per cent on the back of these robust looking half-year figures - indeed, add back acquisition adjustments and reorganisation costs, and underlying operating profits rose 45 per cent to £59.5m. Moreover, strong cash flow from its existing drugs should support new product development.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now